Long-Term Clinical Studies in the Outpatient Sector-Medullary Carcinoma of the Thyroid as an Example.
作者信息
Kroiß Matthias
出版信息
Dtsch Arztebl Int. 2024 Oct 4;121(20):655-656. doi: 10.3238/arztebl.m2024.0185.
Abstract
摘要
相似文献
1
Long-Term Clinical Studies in the Outpatient Sector-Medullary Carcinoma of the Thyroid as an Example.门诊部门的长期临床研究——以甲状腺髓样癌为例。
Dtsch Arztebl Int. 2024 Oct 4;121(20):655-656. doi: 10.3238/arztebl.m2024.0185.
2
Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.《散发性与家族性髓样甲状腺癌的基因组学和表观基因组学研究》
Endocr Pathol. 2021 Mar;32(1):35-43. doi: 10.1007/s12022-021-09664-3. Epub 2021 Jan 25.
3
RET gene mutation analysis and long-term clinical outcomes of medullary thyroid cancer patients.RET 基因突变分析与甲状腺髓样癌患者的长期临床结局。
Nucl Med Commun. 2020 Nov;41(11):1136-1142. doi: 10.1097/MNM.0000000000001264.
4
High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma.HHLA2 高表达预示着甲状腺髓样癌的预后不良。
Jpn J Clin Oncol. 2022 Jul 8;52(7):759-765. doi: 10.1093/jjco/hyac040.
5
Medullary thyroid carcinoma: long-term outcomes of surgical treatment.甲状腺髓样癌：手术治疗的长期结果。
Ann Surg Oncol. 2011 Jan;18(1):219-25. doi: 10.1245/s10434-010-1339-y. Epub 2010 Sep 28.
6
[Reoperation of medullary thyroid carcinoma: long-term results].[甲状腺髓样癌再次手术：长期结果]
Ann Chir. 2001 Oct;126(8):762-7. doi: 10.1016/s0003-3944(01)00609-5.
7
[Expression and clinical significance of Ki67 and calcitonin in medullary thyroid carcinoma].甲状腺髓样癌中Ki67和降钙素的表达及临床意义
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Dec;28(24):1921-4.
8
Sporadic medullary thyroid carcinoma: clinical data from a university hospital.散发性甲状腺髓样癌：一家大学医院的临床数据。
Clinics (Sao Paulo). 2009 May;64(5):379-86. doi: 10.1590/s1807-59322009000500002.
9
Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine.人甲状腺C细胞中胰高血糖素样肽-1受体（GLP-1受体）和CD26的表达：甲状腺C细胞瘤发生与基于肠促胰岛素的药物的关联
Oncol Lett. 2017 Apr;13(4):2684-2690. doi: 10.3892/ol.2017.5752. Epub 2017 Feb 20.
本文引用的文献
1
The Long-Term Cure of Patients With Hereditary Medullary Thyroid Carcinoma: 40 Years of Follow-Up in a Single Center.遗传性髓样甲状腺癌患者的长期治愈：单中心40年随访
Dtsch Arztebl Int. 2024 Oct 4;121(20):657-664. doi: 10.3238/arztebl.m2024.0174.
2
Phase 3 Trial of Selpercatinib in Advanced -Mutant Medullary Thyroid Cancer.塞尔帕替尼治疗晚期突变型甲状腺髓样癌的 3 期临床试验。
N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21.
3
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.美国甲状腺协会修订的甲状腺髓样癌管理指南。
Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335.
4
Cabozantinib in progressive medullary thyroid cancer.卡博替尼治疗进展性甲状腺髓样癌。
J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3.
5
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.2A型多发性内分泌腺瘤病中RET原癌基因的种系突变。
Nature. 1993 Jun 3;363(6428):458-60. doi: 10.1038/363458a0.
6
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.一种与2B型多发性内分泌腺瘤病和散发性甲状腺髓样癌相关的RET原癌基因突变。
Nature. 1994 Jan 27;367(6461):375-6. doi: 10.1038/367375a0.
7
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.MEN2A和MEN2B的种系突变使RET作为主要转化基因被激活。
Science. 1995 Jan 20;267(5196):381-3. doi: 10.1126/science.7824936.
8
Activation of a novel human transforming gene, ret, by DNA rearrangement.通过DNA重排激活一种新型人类转化基因ret
Cell. 1985 Sep;42(2):581-8. doi: 10.1016/0092-8674(85)90115-1.
9
Hypercalcitoninaemia in patients with pheochromocytoma.
Klin Wochenschr. 1978 Jul 15;56(14):697-701. doi: 10.1007/BF02429104.
Zotero 插件